NFE2L2抗体

+ +

•  

   

     Black line: Control Antigen (100 ng); Purple line: Antigen(10ng); Blue line: Antigen (50 ng); Red line: Antigen (100 ng);    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human stomach cancer tissues using NFE2L2 mouse mAb with DAB staining.    

  
  

The NFE2L2 antibody is a crucial tool for studying the nuclear factor erythroid 2-related factor 2 (NFE2L2. also known as Nrf2), a master regulator of cellular antioxidant responses. Nrf2 is a transcription factor that binds to antioxidant response elements (AREs) in the promoter regions of target genes, activating their expression under oxidative or electrophilic stress. These genes encode detoxifying enzymes (e.g., NAD(P)H quinone dehydrogenase 1), glutathione synthesis proteins, and phase II drug-metabolizing enzymes, which collectively protect cells against oxidative damage, inflammation, and carcinogenesis.

NFE2L2 antibodies are widely used in research to detect Nrf2 protein levels, localization, and activity in various disease models, including cancer, neurodegenerative disorders, and metabolic syndromes. They are employed in techniques like Western blotting, immunohistochemistry, immunofluorescence, and chromatin immunoprecipitation (ChIP) to study Nrf2's regulation by KEAP1 (Kelch-like ECH-associated protein 1), which targets Nrf2 for ubiquitination and degradation under basal conditions. Dysregulation of the Nrf2-KEAP1 pathway is implicated in chemoresistance, chronic inflammation, and tumor progression, making NFE2L2 antibodies essential for exploring therapeutic strategies targeting this pathway. Researchers also use these antibodies to evaluate the efficacy of Nrf2 activators (e.g., sulforaphane) in preclinical studies.